secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2026-06-04T20:15:33+00:00
Accession:  0001493152-26-027274
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech terminates Catalyst advisory agreement; shifts to soft tissue/bone fusion strategy
--------------------------------------------------------------------------------

- On June 2, 2026, Sanara MedTech and The Catalyst Group mutually terminated their March 2023 advisory agreement.
- Termination due to shift in strategy to focus on soft tissue repair and bone fusion surgical products.
- No fee or penalty paid in connection with termination; certain covenants (indemnification, confidentiality) remain in effect.
- Chairman Ronald T. Nixon is founder/managing partner of Catalyst and holds >5% beneficial ownership of Sanara MedTech.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315226027274/0001493152-26-027274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315226027274/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-027274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer